The GuardOne clinical trial: A first-in-human, open-label, multinational phase 1/2 study of AVR-RD-02 ex vivo lentiviral vector, autologous gene therapy for Gaucher diseaseLeslie K. Jacobsen, Chris Mason, Julie A. Kerner et al.|Molecular Genetics and Metabolism|2021Cited by 1